Novartis Reveals Phase III GCAptAIN Trial Outcomes: Cosentyx Misses Primary Target for Giant Cell Arteritis

Novartis has disclosed the preliminary findings from its Phase III GCAptAIN study, assessing Cosentyx® (secukinumab) for the treatment of giant cell arteritis (GCA), a severe inflammatory disorder predominantly affecting individuals over 50. Regrettably, the study failed to meet its primary endpoint of sustained remission at Week 52 in patients with newly diagnosed or recurring GCA.

The study evaluated Cosentyx alongside a 26-week glucocorticoid (steroid) taper, comparing it to a placebo with a 52-week steroid taper. Although the primary objective was not met, Cosentyx demonstrated numerically better results than placebo in reducing cumulative steroid use and steroid-related toxicity, though these benefits lacked statistical significance. The safety profile of Cosentyx in GCA patients remained consistent with previous studies and over a decade of real-world application across various inflammatory diseases.

Dr. Shreeram Aradhye, President of Development and Chief Medical Officer at Novartis, commented on the trial’s outcome, stating, “Though the Phase III GCAptAIN results did not mirror the encouraging results from the Phase II trial, we are dedicated to advancing scientific progress and addressing unmet needs.” Novartis intends to conduct a thorough analysis of the data and present detailed results at an upcoming scientific conference.

The GCAptAIN trial (NCT04930094) was a comprehensive, global, randomized, double-blind, placebo-controlled study spanning 27 countries. Participants received either Cosentyx 300 mg, Cosentyx 150 mg, or placebo, each paired with different steroid tapering regimens. The primary aim was to assess whether the 300 mg Cosentyx dose with a shorter steroid duration could more effectively maintain remission compared to placebo with a longer steroid regimen.

Cosentyx, a fully human monoclonal antibody targeting interleukin-17A (IL-17A)—a critical inflammation driver—is approved for multiple inflammatory conditions such as psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa, having treated over 1.8 million patients globally since 2015. Its use is backed by robust clinical evidence and extensive safety data.

Giant cell arteritis (GCA), the most prevalent form of systemic vasculitis, poses significant risks including permanent vision loss and aortic aneurysms, classifying it as a medical emergency. It also severely affects quality of life with symptoms like chronic fatigue, cognitive decline, and loss of independence.

Despite the disappointing GCAptAIN results, they underscore the complexities of managing GCA and the necessity for continued research. Novartis remains committed to deepening its understanding of the disease and developing innovative solutions to enhance patient outcomes.